Early Approval For Astra's Asthma Drug Stuns Analysts
In a blow to GlaxoSmithKline Plc, rival AstraZeneca Plc has secured a surprisingly early U.S. Food and Drug Administration approval for Symbicort, an asthma drug that will compete directly with Glaxo's...To view the full article, register now.
Already a subscriber? Click here to view full article